Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients
The standard of care for glioblastoma (GB) is surgery followed by concurrent radiation therapy (RT) and temozolomide (TMZ) and then adjuvant TMZ. This regime is associated with increased survival but also increased occurrence of equivocal imaging findings, e.g., tumor progression (TP) versus treatm...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-12-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S193652331400117X |
id |
doaj-67db5518250f4c009e1718e201a41d9a |
---|---|
record_format |
Article |
spelling |
doaj-67db5518250f4c009e1718e201a41d9a2020-11-24T21:31:38ZengElsevierTranslational Oncology1936-52331944-71242014-12-017675275810.1016/j.tranon.2014.10.004Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma PatientsCameron J. Koch0Robert A. Lustig1Xiang-Yang Yang2Walter T. Jenkins3Ronald L. Wolf4Maria Martinez-Lage5Arati Desai6Dewight Williams7Sydney M. Evans8Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USADepartment of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA The standard of care for glioblastoma (GB) is surgery followed by concurrent radiation therapy (RT) and temozolomide (TMZ) and then adjuvant TMZ. This regime is associated with increased survival but also increased occurrence of equivocal imaging findings, e.g., tumor progression (TP) versus treatment effect (TE), which is also referred to as pseudoprogression (PsP). Equivocal findings make decisions regarding further treatment difficult and often delayed. Because none of the current imaging assays have proven sensitive and specific for differentiation of TP versus TE/PsP, we investigated whether blood-derived microvesicles (MVs) would be a relevant assay. METHODS: 2.8 ml of citrated blood was collected from patients with GB at the time of their RT simulation, at the end of chemoradiation therapy (CRT), and multiple times following treatment. MVs were collected following multiple centrifugations (300g, 2500g, and 15,000g). The pellet from the final spin was analyzed using flow cytometry. A diameter of approximately 300 nm or greater and Pacific Blue–labeled Annexin V positivity were used to identify the MVs reported herein. RESULTS: We analyzed 19 blood samples from 11 patients with GB. MV counts in the patients with stable disease or TE/PsP were significantly lower than patients who developed TP (P = .014). CONCLUSION: These preliminary data suggest that blood analysis for MVs from GB patients receiving CRT may be useful to distinguish TE/PsP from TP. MVs may add clarity to standard imaging for decision making in patients with equivocal imaging findings. http://www.sciencedirect.com/science/article/pii/S193652331400117X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cameron J. Koch Robert A. Lustig Xiang-Yang Yang Walter T. Jenkins Ronald L. Wolf Maria Martinez-Lage Arati Desai Dewight Williams Sydney M. Evans |
spellingShingle |
Cameron J. Koch Robert A. Lustig Xiang-Yang Yang Walter T. Jenkins Ronald L. Wolf Maria Martinez-Lage Arati Desai Dewight Williams Sydney M. Evans Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients Translational Oncology |
author_facet |
Cameron J. Koch Robert A. Lustig Xiang-Yang Yang Walter T. Jenkins Ronald L. Wolf Maria Martinez-Lage Arati Desai Dewight Williams Sydney M. Evans |
author_sort |
Cameron J. Koch |
title |
Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients |
title_short |
Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients |
title_full |
Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients |
title_fullStr |
Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients |
title_full_unstemmed |
Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients |
title_sort |
microvesicles as a biomarker for tumor progression versus treatment effect in radiation/temozolomide-treated glioblastoma patients |
publisher |
Elsevier |
series |
Translational Oncology |
issn |
1936-5233 1944-7124 |
publishDate |
2014-12-01 |
description |
The standard of care for glioblastoma (GB) is surgery followed by concurrent radiation therapy (RT) and temozolomide (TMZ) and then adjuvant TMZ. This regime is associated with increased survival but also increased occurrence of equivocal imaging findings, e.g., tumor progression (TP) versus treatment effect (TE), which is also referred to as pseudoprogression (PsP). Equivocal findings make decisions regarding further treatment difficult and often delayed. Because none of the current imaging assays have proven sensitive and specific for differentiation of TP versus TE/PsP, we investigated whether blood-derived microvesicles (MVs) would be a relevant assay. METHODS: 2.8 ml of citrated blood was collected from patients with GB at the time of their RT simulation, at the end of chemoradiation therapy (CRT), and multiple times following treatment. MVs were collected following multiple centrifugations (300g, 2500g, and 15,000g). The pellet from the final spin was analyzed using flow cytometry. A diameter of approximately 300 nm or greater and Pacific Blue–labeled Annexin V positivity were used to identify the MVs reported herein. RESULTS: We analyzed 19 blood samples from 11 patients with GB. MV counts in the patients with stable disease or TE/PsP were significantly lower than patients who developed TP (P = .014). CONCLUSION: These preliminary data suggest that blood analysis for MVs from GB patients receiving CRT may be useful to distinguish TE/PsP from TP. MVs may add clarity to standard imaging for decision making in patients with equivocal imaging findings.
|
url |
http://www.sciencedirect.com/science/article/pii/S193652331400117X |
work_keys_str_mv |
AT cameronjkoch microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT robertalustig microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT xiangyangyang microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT waltertjenkins microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT ronaldlwolf microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT mariamartinezlage microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT aratidesai microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT dewightwilliams microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients AT sydneymevans microvesiclesasabiomarkerfortumorprogressionversustreatmenteffectinradiationtemozolomidetreatedglioblastomapatients |
_version_ |
1725960640013533184 |